Welcome to our dedicated page for Theravance Bioph SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theravance Biopharma, Inc. (NASDAQ: TBPH) SEC filings page aggregates the company’s regulatory disclosures, allowing investors to review how this biopharmaceutical issuer reports its financial condition, clinical milestones, and material events. Theravance Biopharma is incorporated in the Cayman Islands and files with the U.S. Securities and Exchange Commission under Commission File Number 001-36033. Its current reports on Form 8-K provide insight into quarterly financial results, strategic transactions, patent settlements, and key clinical and regulatory developments.
Current reports (Form 8-K) for Theravance Biopharma include items on results of operations and financial condition, where the company furnishes press releases and slide decks summarizing quarterly revenue, collaboration income from YUPELRI (revefenacin) inhalation solution, research and development spending, and cash position. Other 8-K filings describe clinical milestones, such as completion of enrollment in the pivotal Phase 3 CYPRESS study of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), and regulatory approvals such as Viatris securing NMPA approval in China for YUPELRI.
Theravance Biopharma’s 8-K filings also document patent and litigation developments, including settlement agreements related to YUPELRI patents with generic manufacturers under the Hatch-Waxman Act. These filings outline licensed launch dates for potential generic versions and note that certain settlements are subject to review by U.S. competition authorities.
Through this filings page, users can access the company’s furnished exhibits, including press releases and investor slide decks referenced in Forms 8-K, to better understand how Theravance Biopharma describes its respiratory franchise, late-stage ampreloxetine program, and strategic review activities. Stock Titan’s platform adds AI-powered summaries that explain the key points of lengthy filings, highlight material disclosures, and help readers quickly identify items related to YUPELRI collaboration economics, ampreloxetine clinical progress, and other events that may be relevant when analyzing TBPH stock.
Theravance Biopharma reported that its Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension did not meet the primary OHSA composite endpoint, and the program will be wound down. The Board’s Strategic Review Committee is accelerating its evaluation of alternatives, including a possible sale of the company, with no assurance any transaction will occur.
The company announced a major restructuring that will eliminate its R&D organization, reduce G&A by about 50%, and cut operating expenses by roughly 60%, or about $70 million, impacting around half of the workforce. Management expects these actions, together with YUPELRI revenue, to support approximately $60–$70 million of annualized cash flow starting in Q3 2026.
Theravance highlighted cash of $326.5 million as of December 31 2025, expected cash of about $400 million at the end of Q1 2026 after receiving a $25 million YUPELRI milestone and a $50 million TRELEGY milestone, and a potential additional $100 million TRELEGY milestone tied to 2026 global sales. YUPELRI U.S. net sales reached $266.6 million in 2025, up 12% year over year.
Theravance Biopharma, Inc. reported an insider equity transaction by Chief Executive Officer Rick E. Winningham. On the reported date, 74,975 ordinary shares were withheld at an implied price of $19.66 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This withholding was with the company and did not involve any open market trade. After the transaction, Winningham directly held 1,576,094 ordinary shares. He also had indirect holdings of 23,400 ordinary shares as custodian and 92,567 ordinary shares held by a trust.
Theravance Biopharma, Inc. executive Aziz Sawaf, SVP & Chief Financial Officer, reported a tax-related share disposition. On February 20, 2026, 20,672 Ordinary Shares were withheld at $19.66 per share to satisfy tax obligations from vesting restricted stock units. This withholding was conducted with the company and did not involve any open market trade. After this transaction, Sawaf directly held 316,123 Ordinary Shares.
Theravance Biopharma, Inc. senior vice president Aine Miller reported a tax-related share disposition linked to vesting equity awards. On the transaction date, 16,851 Ordinary Shares were withheld at a price of $19.66 per share to cover tax obligations from previously granted restricted stock units vesting. The shares were withheld by the company rather than sold in the open market, and Miller’s directly owned stake after this tax-withholding transaction was 184,161 Ordinary Shares.
Theravance Biopharma SVP Brett A. Grimaud reported a tax-related share disposition. On this Form 4, 20,833 Ordinary Shares were withheld at $19.66 per share to cover tax obligations from vesting restricted stock units. This was a transaction with the company, not an open-market trade, and left him holding 334,449 shares directly.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a tax-related share disposition connected to the vesting of restricted stock units. On this Form 4, 13,929 ordinary shares were withheld at a price of $19.66 per share to satisfy tax obligations, in a transaction with the issuer rather than through the open market. Following this tax-withholding event, Farnum directly owned 263,766 ordinary shares.
Theravance Biopharma, Inc. received an updated beneficial ownership report from Newtyn entities. As of December 31, 2025, Newtyn Management, LLC may be deemed to beneficially own 4,300,000 ordinary shares, representing 8.5% of the company’s ordinary shares based on 50,672,431 shares outstanding as of November 3, 2025.
Newtyn TE Partners, LP directly holds 2,678,900 ordinary shares, or 5.3% of the class, while Newtyn Partners, LP holds 1,621,100 shares, all managed by Newtyn Management. The reporting persons certify the shares were acquired and are held without the purpose or effect of changing or influencing control of Theravance Biopharma.
Theravance Biopharma, Inc. filed a Form 8-K to furnish an investor presentation under Regulation FD. Members of the management team are holding one-on-one meetings with analysts and investors in San Francisco, California from January 12–15, 2026, using a corporate slide presentation. That slide deck, entitled “Corporate Presentation – January 2026”, is provided as Exhibit 99.1 and incorporated by reference into the report.
Theravance Biopharma, Inc. (TBPH)11/20/2025. The officer had 18,627 ordinary shares withheld at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from the vesting of previously granted restricted stock units.
After this tax-withholding event, the officer directly beneficially owned 336,795 ordinary shares. The explanation clarifies that this was a share withholding with the issuer and did not involve an open market transaction.
Theravance Biopharma, Inc. (TBPH) reported an insider equity transaction by a senior executive. The reporting person, identified as an officer with the title "SVP, DEV & HEAD OF IRE OFFICE," filed a Form 4 for activity dated 11/20/2025.
The filing shows that 6,989 ordinary shares were withheld and disposed of at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from vesting restricted stock units. After this tax withholding, the reporting person beneficially owns 201,012 ordinary shares, held directly.
An explanation clarifies that the share withholding was with the issuer and did not involve an open market transaction. The form is filed for one reporting person and is signed by an attorney-in-fact on 11/24/2025.